Immunocore Secures Reimbursement Agreement In England For KIMMTRAK To Treat HLA-A*02:01-Positive Adults With Unresectable Or Metastatic Uveal Melanoma
Immunocore Secures Reimbursement Agreement In England For KIMMTRAK To Treat HLA-A*02:01-Positive Adults With Unresectable Or Metastatic Uveal Melanoma
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
"Today is a landmark day for the uveal melanoma community, with NICE's recommendation of the first treatment to prolong survival in HLA-A*02:01-positive adults with metastatic or unresectable uveal melanoma. Uveal melanoma is a very rare form of melanoma which requires different clinical management. The option to prescribe tebentafusp is a step change for patients and their families, and we continue to support the process so that there is reimbursement for the therapy across the UK for all eligible patients," said Susanna Daniels, CEO of Melanoma Focus.
Immunocore在英格兰宣布与KIMMTRAK▼达成报销协议，以治疗HLA-A*02:01阳性的不可切除或转移性葡萄膜黑色素瘤成人。
"今天是葡萄膜黑色素瘤社区的一个里程碑日，NICE推荐了第一种治疗方法，以延长HLA-A*02:01阳性成人的生存期，这些成人患有转移性或不可切除的葡萄膜黑色素瘤。葡萄膜黑色素瘤是一种非常罕见的黑色素瘤，需采用不同的临床管理。开处方tebentafusp的选项是对患者和他们家庭的重大改变，我们将继续支持这一过程，以便在英国为所有符合条件的患者提供该疗法的报销，" Melanoma Focus的首席执行官Susanna Daniels表示。